A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Administered By

Awarded By

Contributors

Start/End

  • June 8, 2020 - October 31, 2023